Gene One Life Science

Gene One Life Science Current Liabilities

The Current Liabilities of Gene One Life Science (011000.KS) as of Oct 27, 2026 is 52.51 B KRW. In the previous year, Current Liabilities was 52.61 B KRW — a change of -0.20% (lower).

Current Liabilities

52.51 BKRW

YoY

-0.20%

Last updated:

Current Liabilities of Gene One Life Science is 2025 52.51 B KRW. Current Liabilities of Gene One Life Science was 2024 52.61 B KRW. It decreases by -0.20% lower compared to the previous year.

The Gene One Life Science Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
30.05 B KRW
Jan 1, 2019
26.53 B KRW
Jan 1, 2020
41.12 B KRW
Jan 1, 2021
42.30 B KRW
Jan 1, 2022
42.48 B KRW
Jan 1, 2023
27.12 B KRW
Jan 1, 2024
52.61 B KRW
Jan 1, 2025
52.51 B KRW
The Gene One Life Science Current Liabilities history
YEARCurrent LiabilitiesYoY
52.51 BKRW-0.20%
52.61 BKRW+94.03%
27.12 BKRW-36.17%
42.48 BKRW+0.42%
42.30 BKRW+2.88%
41.12 BKRW+55.00%
26.53 BKRW-11.71%
30.05 BKRW+218.45%
9.43 BKRW-76.34%
39.88 BKRW+462.33%
7.09 BKRW+58.59%
4.47 BKRW-32.81%
6.66 BKRW-67.84%
20.69 BKRW+260.34%
5.74 BKRW-23.35%
7.49 BKRW-31.16%
10.88 BKRW+33.35%
8.16 BKRW+4.31%
7.83 BKRW+130.02%
3.40 BKRW+83.20%
1.86 BKRW-9.99%
2.06 BKRW-0.96%
2.08 BKRW-35.31%
3.22 BKRW-32.48%
4.77 BKRW-44.97%
8.67 BKRW-12.18%
9.87 BKRW-18.26%
12.07 BKRW-28.81%
16.96 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Gene One Life Science Stock analysis

What does Gene One Life Science do? GeneOne Life Science, Inc. generates revenue through its biomedical contract manufacturing organization (CMO) services, producing DNA vaccines for disease prevention and treatment. The company also sells wicks under the brand INTERON for use in dress shirts, suits, and caps, and provides biopharmaceutical services including research, development, and manufacturing of plasmid DNA and DNA vaccines. Its leasing business involves nonresidential buildings. The primary buyers for the biomedical CMO services are likely pharmaceutical companies seeking contract manufacturing for DNA vaccines. INTERON wicks are purchased by apparel manufacturers producing dress shirts, suits, and caps. The leasing segment targets commercial property tenants requiring nonresidential space. The company serves the biomedical, textile, and real estate sectors through these distinct business segments. Gene One Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gene One Life Science stock

Current Liabilities of Gene One Life Science is 52.51 B KRW in 2025.

Current Liabilities of Gene One Life Science changed from 52.61 B KRW to 52.51 B KRW, representing a -0.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Gene One Life Science since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Gene One Life Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Gene One Life Science

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Gene One Life Science